Subsequent Events

9 Months Ended

Jan. 23, 2026

Subsequent Events [Abstract]

Subsequent Events

Subsequent Events

Subsequent to quarter-end, on February 3, 2026, the Company announced its intention to exercise its option to acquire CathWorks Ltd. (CathWorks), a privately held medical device company. The acquisition expands the Coronary & Peripheral Vascular division within the Cardiovascular portfolio by aiming to transform how coronary artery disease is diagnosed and treated. The acquisition option is valued at up to $585 million with potential revenue-based contingent consideration payments post-acquisition. The Company also holds a previous equity investment in CathWorks and anticipates the acquisition will be accounted for as a step-acquisition at the time of closing in accordance with ASC 805. This acquisition is expected to be completed by the end of fiscal year 2026, subject to applicable regulatory approvals and other customary closing conditions. As the acquisition has not yet closed, the Company has not completed the purchase price allocation of this acquisition and an estimate of the full financial effect of the transaction cannot be made. In addition, all other business combination disclosures are not available.

On February 20, 2026, the U.S. Supreme Court ruled that President Trump's tariff policies under the International Emergency Economic Powers Act are unconstitutional. The Company will continue to monitor the situation and the impact to our results of operations.